Team unearths what may be secret weapon against antibiotic resistance

A photo of the fungus Aspergillus versicolor. Credit: McMaster University

A fungus living in the soils of Nova Scotia could offer new hope in the pressing battle against drug-resistant germs that kill tens of thousands of people every year, including one considered a serious global threat.

A team of researchers led by McMaster University has discovered a fungus-derived molecule, known as AMA (Aspergillomarasmine A), which is able to disarm one of the most dangerous antibiotic-resistance genes: NDM-1 or New Delhi Metallo-beta-Lactamase-1, identified by the World Health Organization as a global public health threat.

"This is public enemy number one," explains Gerry Wright, director of the Michael G. DeGroote Institute for Infectious Disease Research at McMaster University.

"It came out of nowhere, it has spread everywhere and has basically killed our last resource of antibiotics, the last pill on the shelf, used to treat serious infections," he says.

Discovering the properties of the fungus-derived molecule is critical because it can provide a means to target and rapidly block the drug-resistant pathogens that render carbapenem antibiotics—a class of drugs similar to penicillin—ineffective.

"Simply put, the molecule knocks out NDM-1 so the antibiotics can do their job," says Wright.

Seeking an answer to the riddle of resistance in the natural environment is a far more promising approach than trying to discover new antibiotics, a challenge which has perplexed scientists for decades. No new classes of antibiotics have been discovered since the late 1980s, leaving physicians with very few tools to fight life-threatening infections.

"Not only do we have the emergence of an gene that is targeting the last drug resource we have left, but it is carried by organisms that cause all sorts of challenging diseases and are multi-drug-resistant already. It has been found not only in clinics but in the environment—in contaminated water in South Asia—which has contributed to its spread over the globe," explains Wright. "Our thinking was that if we could find a molecule that blocks NDM-1 then these antibiotics would be useful again."

Wright and his team from McMaster, University of British Columbia and Cardiff University in Wales created a sophisticated screening method to take the NDM-1 gene, combine it with harmless E. coli bacteria and then isolate a molecule capable of stopping NDM-1 in its tracks.

Scientists unearth what may be secret weapon against antibiotic resistance
Andrew King, a chemical biology graduate student at McMaster University examines a chemical used in drug discovery research. Credit: McMaster University

NMD-1 requires zinc to thrive but finding a way to remove zinc from it without causing a toxic effect in humans was a daunting task, until the discovery of the fungal molecule, which appears to perform the job naturally and harmlessly.

Scientists then tested the theory on mice infected with an NDM-1 expressing superbug. The mice that received a combination of the AMA molecule and a carbapenem antibiotic survived, while those that received either an antibiotic or AMA alone to fight the infection did not survive.

"This will solve one aspect of a daunting problem. AMA rescues the activity of carbapenem antibiotics, so instead of having no , there will be some," says Wright. "This is a made-in-Canada solution for a global problem."

"Antibiotic resistance may be the most urgent and perplexing challenge facing health-care researchers today," says Dr. John Kelton, dean of the Michael G. DeGroote School of Medicine and vice-president of the Faculty of Health Sciences at McMaster. "This research provides new hope by showing us a completely new way to approach this problem, and none too soon, given the growing risk that superbugs pose to all of us. "

The findings are published online in the current edition of the journal Nature.

"Antibiotic resistance is one of the top public health concerns in Canada and internationally and it represents a research priority for the Canadian Institutes of Health Research (CIHR). It is exciting to see Canadian researchers finding innovative strategies to overcome antimicrobial resistance," says Dr. Marc Ouellette, scientific director of the CIHR Institute of Infection and Immunity.

More information: Aspergillomarasmine A overcomes metallo-beta-lactamase antibiotic resistance, Nature, DOI: 10.1038/nature13445

add to favorites email to friend print save as pdf

Related Stories

Antibiotic-resistant pathogens and poultry

Jun 18, 2014

(Medical Xpress)—With recent headlines about dangerous "superbugs," an outbreak of Salmonella from chicken parts on the West Coast and the announcement by a national restaurant chain that it plans to serve ...

Recommended for you

Cell death proteins key to fighting disease

1 hour ago

Melbourne researchers have uncovered key steps involved in programmed cell death, offering new targets for the treatment of diseases including lupus, cancers and neurodegenerative diseases.

Unlocking the secrets of pulmonary hypertension

17 hours ago

A UAlberta team has discovered that a protein that plays a critical role in metabolism, the process by which the cell generates energy from foods, is important for the development of pulmonary hypertension, a deadly disease.

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

mikael_murstam
5 / 5 (1) Jun 27, 2014
Great news!
Returners
1 / 5 (3) Jun 29, 2014
Great news!


Not great.

if they can make strains of bacteria which product this in the lab, and people have been genetically modifying foods for 2 decades, using bacterial dna, then it's obviously a problem.

They can make bacteria with this gene, as they have done, release it into the wild, offer you a "miracle" solution, which they have already secretly developed ahead of time in the lab, and force you to pay for it, or die.

It's the same old crap really: Treat disease, don't really cure it.

When they run the risk of curing disease, they engineer better diseases, with targeted weaknesses against materials they alone have already developed.

Even if this company hasn't done that, what's to stop someone else doing it?

Secretly release it in some moderately remote place nobody cares about, and watch it spread. By the time anyone realizes the outbreak is a new strain of bacteria it's in full swing. The "new" gene "looks" innocent/natural enough...
Returners
1 / 5 (3) Jun 29, 2014
Drug company waits a calculated amount of time, then, "viola! We discovered the cure!"

The fact they can do it in the lab (which we've known about for decades due to GM foods,) means they CAN do this any time they want.

Any drug company with gene splicing technology can make a super-bug, any time they want, with targeted weaknesses, and reveal the "cure," which they've already had, a few years later.

Capitalism:
Create a problem.
Create a solution.
Release the problem.
Wait a few years.
Reveal the solution you've already had.
Profit.
Returners
1 / 5 (3) Jun 29, 2014
There is a faster way to kill this gene, which would cost very little to accomplish.

Look for a virus which is capable of attacking your most problematic bacteria strains.
Splice the AMA gene into that virus, if possible splice an antibiotic-producing gene into that virus as well.
Release the Virus, which can't infect humans or livestock.
All infected bacterial cells become production facilities for AMA and (the antibiotic,) and those with NDM die.
Those without NDM go through the normal viral production cycle, and may or may not die.
Any survivors are exposed to the excess AMA and antibiotic and probably die.

You've just eliminated your resistant strain, and the resistant gene, and possibly the entire bacterial genus.

But...if a drug company did that, they wouldn't be able to charge money for the "cure" to the drug-resistant bacteria.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.